COPD from an everyday primary care point of view

Area of Science:

• Pulmonary Medicine
• Pharmacoepidemiology
• Real-World Evidence

Background:

• Chronic obstructive pulmonary disease (COPD) management involves various treatment strategies.
• Real-world evidence is crucial for evaluating drug effectiveness in routine clinical practice.
• Understanding treatment superiority within patient groups can optimize COPD care.

Purpose of the Study:

• To evaluate drug superiority for COPD treatments using real-world data.
• To compare the risk of COPD exacerbations across different treatment regimens.
• To identify the most effective combination therapies for COPD patients.

Main Methods:

• Retrospective cohort analysis of 7,890,485 patients from the Spanish BIFAP database.
• Inclusion of incident COPD diagnoses between January 2010 and December 2012.
• Cox regression analysis to compare exacerbation hazards across no therapy, monotherapy, double therapies (with/without corticoids), and triple therapy.

Main Results:

• 27,739 COPD patients analyzed (median age 64, 69% male, 70% smokers).
• Previous exacerbation was the strongest risk factor (HR=1.82).
• Budesonide/formoterol showed lower exacerbation risk than salmeterol/fluticasone (HR=1.16); no differences found for other regimens.

Conclusions:

• Budesonide/formoterol combination therapy is associated with fewer COPD exacerbations than salmeterol/fluticasone.
• Monotherapy, double therapy without corticoids, and triple therapy showed no significant differences in exacerbation rates.
• Real-world data supports budesonide/formoterol as a potentially superior option for managing COPD exacerbations.